AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 281 min read

Opaleye Management Inc. purchased $1K of ACOG (indirect holdings)

Opaleye Management Inc. purchased 130 indirectly-held shares of Alpha Cognition Inc. (ACOG) at $7.90 on 2026-07-24.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Jul 28, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ACOG
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

Low
01

Why it matters

The newest concrete fact is the reported purchase of 130 shares at $7.90 on 2026-07-24, totaling $1,027, with holdings after transaction of 2,995,323 shares. No new business, financial, or regulatory development is disclosed.

02

Market read

This is a routine insider Form 4 with small dollar value and indirect ownership, offering limited incremental trading signal.

03

What to watch

Indirect holdings and small notional value reduce interpretability; without follow-on disclosures (e.g., larger buys, sales, or corporate actions), trading impact is likely minimal.

Relevance 3/10Novelty 2/10Timing: filed 2026-07-28, discloses a small Form 4 purchase on 2026-07-24

Background

The filing is an SEC Form 4 insider transaction: Opaleye Management Inc. (10% owner) reports an indirect open-market purchase of ACOG shares.

Market effects

Sector

None. This is a routine insider transaction with no operational or guidance signal.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

A non-10b5-1 open-market purchase can be interpreted as insider conviction, but the disclosed size is small and indirect, limiting signal strength.

Key entities

  • issuer
    Alpha Cognition Inc.

    Subject of the Form 4 insider transaction disclosure (ACOG).

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ACOG insider trading history →

Related articles

AUG 15
$ACOGMed

Alpha Cognition Q2 Earnings Call Highlights

Alpha Cognition (NASDAQ:ACOG) said ZUNVEYL demand rose each month in Q2, with June the strongest month to date, and management attributed growth to demand rather than wholesaler or pharmacy stocking. Payer formulary activation lagged expectations, with payer access the key near-term friction. The company reported BEACON study positive top-line results, lowered 2026 operating expense guidance to $50M-$54M, and had $41.4M cash as of June 30.

yahoo.com6 min
AUG 14
$ACOGHighAI 9/10

Why is Alpha Cognition stock surging today?

Alpha Cognition (ACOG) shares rose about 12.1% pre-open after its Q2 2026 earnings call. ZUNVEYL net product revenue was about $6.0M, up 71% sequentially and from $1.7M in Q2 2025. Net loss narrowed to $8.8M ($0.40/share). Gross product margin was ~94%, and full-year 2026 operating expense guidance was cut to $50M-$54M; profitability target remains 2027.

investing.com4 min
JUL 29
$ACOGMed

Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer’s Disease

Alpha Cognition Inc. (NASDAQ: ACOG) said the European Patent Office granted a European patent covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for use in treating mild-to-moderate Alzheimer’s disease. The patent covers specific solid form, compositions, manufacturing and medical-use claims, with potential protection into 2042, subject to requirements.

thestarphoenix.com3 min